Nxera Pharma Secures Taiwan Approval for Insomnia Drug QUVIVIQ
Event summary
- Nxera Pharma’s QUVIVIQ (daridorexant) 25mg and 50mg received approval in Taiwan for insomnia treatment.
- Holling Bio-Pharma Corp. will commercialize QUVIVIQ in Taiwan, targeting 4–5 million patients.
- Approval was granted under Taiwan’s Streamlined Review Designation pathway.
- Launch is planned for 2026, with Nxera eligible for milestone payments and royalties.
The big picture
Nxera Pharma’s approval in Taiwan marks another step in its strategy to expand access to specialty medicines across the APAC region. The Streamlined Review Designation pathway expedited the process, highlighting Taiwan’s growing role in fast-tracking innovative treatments. With insomnia affecting 12-20% of Taiwan’s adult population, QUVIVIQ’s differentiated mechanism of action positions it as a key player in the competitive sleep disorder market.
What we're watching
- Regulatory Momentum
- Whether Nxera can replicate this approval success in other APAC markets, particularly South Korea, where it submitted a marketing application in March 2026.
- Commercial Execution
- The pace at which Holling Bio-Pharma can launch and scale QUVIVIQ in Taiwan, given its extensive experience in the CNS field.
- Revenue Impact
- How near-term sales milestones and royalties from QUVIVIQ will contribute to Nxera’s financial performance in 2026.
Related topics